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Objectives: Major operative trauma like aorta-coronary bypass operation
may lead to postoperative immunodisturbance, putting the patient at an
increased risk for infection and sepsis. The monocyte/macrophage system
and the endotoxin receptor CD14 are important in the early recognition
and elimination of invading bacteria. The aim of this study was to analyze
changes in membrane-associated CD14 and soluble CD14 during and after
cardiac involving cardiopulmonary bypass. Methods: We studied numbers
of leukocytes, monocytes, and monocyte subpopulations, expression of
monocyte membrane-associated CD14 and plasma levels of soluble CD14 in
10 patients (63 6 8 years of age), who underwent elective cardiopulmonary
bypass. Results: Cardiopulmonary bypass induced marked postoperative
monocytosis, which was maximal 20 hours after the operation (485 6 242
cells/ml before, 1080 6 264 cells/ml 20 hours after surgery). Expression of
membrane-associated CD14 on classical CD1411 monocytes decreased
significantly by 40%, reaching a nadir 20 hours after surgery (p < 0.05). At
the time of maximal membrane-associated CD14 suppression, the levels of
soluble CD14 measured by enzyme-linked immunosorbent assay were
clearly increased (3.2 6 1.0 mg/ml before versus 5.6 6 1.0 mg/ml 20 hours
after, p < 0.001). No significant change of the percentage of small (a) and
large (b) forms of soluble CD14 was found. Conclusions: Cardiopulmonary
bypass leads to reduced membrane-associated CD14 expression on periph-
eral blood monocytes and increased levels of soluble CD14 through
shedding or secretion of membrane-associated CD14 from the cell surface.
These findings indicate that bypass is associated with significant monocyte
activation. (J Thorac Cardiovasc Surg 1998;115:1172-8)
Patients undergoing cardiopulmonary bypass(CPB) frequently manifest a generalized sys-
temic inflammatory response syndrome. Clinically,
these reactions are reflected in postoperative leuko-
cytosis, fever, and extravascular fluid accumulation,
which may be associated with prolonged recovery
and occasionally with serious organ dysfunction.1-3
Current knowledge suggests that activation of circu-
lating leukocytes, platelets, and vascular wall com-
ponents, such as endothelial cells, during CPB is
involved in this inflammatory response. However,
neither the exact mechanism(s) of activation nor the
sequelae of such inflammation are fully understood.
Complement activation and neutropenia occur
during CPB, and functional signs of leukocyte acti-
vation after cardiac operation, including the release
of proteolytic enzymes, free radical production, and
changes in leukocyte adhesiveness, have been re-
ported.4-6 Furthermore, measures of cell-mediated
immunity, such as lymphocyte responsiveness to
mitogens and antigen presentation, have been shown
to be seriously impaired in patients after CPB.7
The monocyte/macrophage cell system is believed
to play a central role in regulating acute inflamma-
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tory responses. During CPB, monocytes release
proinflammatory mediators, such as interleukin
(IL)-1b, IL-6, and IL-8.3, 8, 9 Monocytes express
specific cell surface antigens that are of principal
importance in stimulation of these myeloid cells.
CD14 is a 55-kD glycoprotein that exists in both
membrane-associated and soluble forms. Mem-
brane-associated CD14 (mCD14) has been identi-
fied as the main lipopolysaccharide (LPS) (endotox-
in) receptor on leukocytes.10 mCD14 can be
released by cells to yield a soluble protein (sCD14)
that is able to attach to epithelial and endothelial
cells.11
Activation of monocytes through mCD14 triggers
a complex inflammatory response, leading to cyto-
kine release, production of reactive oxygen species,
and production of prostaglandins. Elevated plasma
concentrations of sCD14, together with a reduced
expression of mCD14, have been reported in pa-
tients with pathologic conditions such as sepsis,
infection, or multiple organ failure, and increased
serum levels of sCD14 were associated with a higher
mortality.12, 13
Because the systemic inflammatory response to
CPB is mediated, in part, by monocytes and because
increased plasma levels of sCD14 reflect monocyte
activation we analyzed the effect of elective coronary
artery bypass grafting with CPB on the monocyte
CD14 system.
Patients and methods
Study design. To test the hypothesis that CPB activates
the monocyte CD14 system, markers of monocyte CD14
activity were determined before, during, and after elective
coronary revascularization operation performed with
CPB. Primary measures of monocyte CD14 activity were
the membrane expression of CD14 and plasma concen-
trations of sCD14. Because CPB may differentially effect
the numbers of circulating leukocytes, numbers of leuko-
cytes, monocytes, and monocyte subpopulations were also
determined.
Blood samples were collected before anesthesia, after
15 and 60 minutes of CPB, and at 0, 6, 20, and 44 hours
after completion of the operation. Blood obtained from
five healthy donors (mean age 59 6 7 years, three men
and two women) was used to establish the normal range of
monocyte CD14 activity.
Patients. Ten patients (eight men, two women, mean
age 63 6 8 years) with coronary heart disease undergoing
elective coronary revascularization participated in the
study. The study protocol was approved by the ethical
board of the Faculty of Medicine at the Ludwig-Maximil-
ians-University of Munich, and informed consent was
obtained from each patient.
None of the patients had clinical evidence of acute
infection or underlying immune disease, and none were
prescribed drugs known to interfere with the immune
response before operation. Anesthesia was accomplished
with a standard combination of a narcotic (isoflurane),
muscle relaxant (pancuronium bromide), and analgesic
(fentanyl). In all patients a polypropylene hollow fiber
oxygenator (Maxima Plus PRF, surface area 2.3 m2,
ethylene oxide–sterilized, mean priming volume 2280 ml,
Medtronic, Anaheim, Calif.) was used. The extracorpo-
real circuit was primed with standard electrolyte solution
to which 50 mmol bicarbonate was added. CPB was
instituted at a flow rate of 4.0 6 0.4 L/min. Blood was
anticoagulated by administration of 20,000 to 30,000 IU of
heparin during CPB. The heparin was neutralized by
protamine at the end of CPB. The total time on CPB was
101 6 48 minutes, and the aorta was clamped for an
average of 60 6 31 minutes. Minimal body temperature
reached was 28.4° 6 3.6° C in 50 6 31 minutes after
initiation of CPB. A total of 2.6 6 0.5 distal coronary
anastomoses were performed.
All patients were extubated on the first postoperative
day and transferred from the intensive care unit on the
second postoperative day. Two patients had a rethora-
cotomy within the first postoperative hours because of an
intrathoracic hemorrhage, but recovery was uneventful
otherwise. Two patients were treated with antibiotics for
uncomplicated urinary tract infections at the end of the
first postoperative week.
Leukocyte count. The absolute number of total leuko-
cytes was determined by use of a Coulter Counter T 840
(Coulter, Krefeld, Germany).
Immunofluorescence studies. Monocyte expression of
CD14 and CD16 was studied using two-color immunoflu-
orescence. Briefly, samples of ethylenediaminetetraacetic
acid–anticoagulated blood were drawn and stored on ice
for a maximum of 2 hours. Whole blood, 100 ml, was
reacted with monoclonal antibodies against CD14 (My4-
PE, Coulter) and CD16 (3G8-Fitc, Coulter) or the respec-
tive isotype controls for 20 minutes on ice. Erythrocytes
were lysed, and the leukocytes fixed using the Q-Prep
Lysis Kit (Coulter). Samples were washed twice with cold
phosphate-buffered saline and then analyzed in a FACS-
Can flow cytometer (Becton Dickinson, San Jose, Calif.).
Monocytes (5000 events) were acquired by gating on
forward and side angle scatter. The percentage of nonvi-
able cells determined by staining with propidium iodide
(Sigma, Deisenhofen, Germany) was negligible (, 2%).
For analysis, the data were collected in log mode. The
logarithmic data were transformed to a linear scale of
specific mean fluorescence intensity, and results are ex-
pressed as relative change from preoperative values.
Within the human monocyte/macrophage system, most
monocytes are CD16-negative and exhibit strong CD14
staining. These CD1411 cells (two 11 to denote the
strong expression of CD14) account for about 90% of all
monocytes and represent what is usually referred to as
“monocytes.” CD141CD161 positive cells form a subset
of monocytes that is distinct from the classical monocyte
population. These cells are characterized by a more
mature phenotype and by the inability to produce IL-10.14
The number of CD141CD161 monocytes can be dramat-
ically increased in patients with sepsis.15 Analysis of
CD141CD161 positive cells was performed as previously
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described elsewhere16 (also in http://www.med.uni-
muenchen.de/immuno/ziegler). The number of total
monocytes/ml blood was calculated as total leukocytes/ml
blood 3 % of all CD14 positive cells in the monocyte
scatter gate. The number of CD141CD161 monocytes
per ml was calculated as total monocytes per ml blood 3 %
CD141CD161 monocytes among all CD14-positive
monocytes.
sCD14 detection by Western blotting. Plasma was ob-
tained by centrifugation of whole blood at 800g for 5
minutes at 4° C and stored at –80° C. For sCD14 analysis,
plasma was thawed at 37° C and coagulated by addition of
glass beads. Western blotting was performed as previously
described.17 Briefly, plasma was diluted 1:50 with Lae-
mmli’s reducing sample buffer, boiled, and loaded onto
precast 12.5% polyacrylamide gels (Phastgels, Pharmacia
Biotech, St. Quentin, Yvelines, France). Electrophoresis
was carried out in the presence of sodium dodecylsulfate
in a PhastSystem (Pharmacia). Proteins were transferred
to Hybond-ECL nitrocellulose membranes (Amersham,
Buckinghamshire, United Kingdom) in transfer buffer (48
nmol/L tris-hydroxymethyl-amino methane, 39 nmol/L
glycine pH 9.0 with the addition of 20% methanol) for 16
minutes at 30 mA/gel using a semidry transfer cell (Bio-
Rad). sCD14 glycoproteins were detected by incubation of
the blots with the My4 monoclonal antibody (1 mg/ml) and
visualized by enhanced chemiluminescence (Amersham).
Luminescence was detected by short exposures on Hyper-
film MP films (Amersham). With short exposure times of
the film, the Western blotting for sCD14 is at least
semiquantitative because in titration experiments a linear
relationship between amounts of sCD14 and the densi-
tometry signal was achieved.
sCD14 detection by enzyme-linked immunosorbent as-
say. Plasma concentrations of sCD14 were determined
using a specific enzyme-linked immunosorbent assay
(IBL, Hamburg, Germany).
Statistics. To determine the effect of CPB on monocyte
activity, the time courses of monocyte CD14 expression
and plasma CD14 concentrations were analyzed by use of
an analysis of variance for repeated measures (SigmaStat,
Jandel, San Rafael, Calif.). This method of analysis was
chosen in recognition of the variability in monocyte
populations that can occur between individuals. Where a
significant effect of time was found, differences between
individual time points were evaluated using a Bonferroni
posthoc test. Data are presented as mean 6 standard
deviation. For clarity of presentation, the data presented
in Figs. 1 and 2 are normalized to the preanesthesia value.
Results
CPB induces an initial decrease of monocyte
count followed by postoperative monocytosis. Leu-
kocyte and monocyte counts were within normal
limits preoperatively (5.540 6 2.093 leukocytes/ml
and 485 6 242 monocytes/ml). In contrast to earlier
reports the total leukocyte count did not decrease
significantly after start of CPB. Instead, total leuko-
Fig. 1. Relative changes in the absolute numbers of leukocytes, total monocytes, and CD1411 mono-
cytes. The absolute numbers of total monocytes and monocyte subpopulations were determined by FACS
using directly fluorochrome-conjugated monoclonal antibodies against CD14 (My4-phycoerythrin) and
CD16 (3G8-fluorescein). Preoperative values (t 5 0) were taken as 100%. Subsequent data are given as
relative difference to preoperative values (cells/ml[t] divided by cells/ml[t 5 0]), thus reflecting the factor of
decrease or increase compared with t 5 0. CPB, Cardiopulmonary bypass.
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cyte count increased continuously up to factor 3 at
44 hours after operation (p , 0.05). Fifteen minutes
after initiation of CPB, there was a mild decrease in
monocyte count to 305 6 237 cells/ml, followed 6
hours after the end of the operation by a monocy-
tosis that reached a maximum at 20 hours (1080 6
264 cells/ml, p , 0.05, Fig. 1). Because CPB might
differentially influence monocyte subpopulations,
we also studied the kinetics of classical CD1411
and CD141CD161 monocytes. The major popula-
tion of CD1411 monocytes was decreased during
CPB, with a nadir at 15 minutes (272 6 214 cells/ml
vs 457 6 220 cells/ml during anesthesia). At 6 hours
after operation the number of CD141 monocytes in
peripheral blood had already increased by a factor
of 2.5, reaching a maximum at 20 hours with 911 6
369 cells/ml (p , 0.05, Fig. 1). The CD141CD161
monocytes (48 6 30 cells/ml initially) decreased,
with a nadir at the end of operation (9 6 6 cells/ml)
and increased after operation by factor 1.5 with a
maximum of 69 6 33 cells/ml at 20 hours after
operation (data not shown). Thus in the postopera-
tive phase there is a relative decrease of
CD141CD161 monocytes, which is maximal at 6
hours after operation (9.3% 6 2.4% vs 2.9% 6
2.1%, p , 0.001) and still persists at 20 hours (6.7%
6 3.3%) (data not shown).
mCD14 expression decreases on CD1411 mono-
cytes after CPB. Before operation, mCD14 expres-
sion by CD1411 monocytes was within the normal
range compared with five healthy donors. After the
start of CPB, a temporary increase in mCD14
expression was noted (Fig. 2). mCD14 expression
then decreased, reaching a nadir 40% below initial
values at 20 hours postoperatively (p , 0.05). The
CD141CD161 monocytes are not included in the
above analysis. Cell surface expression of mCD14
did not significantly change in the CD141CD161
monocytes (data not shown).
Plasma sCD14 is increased at the time of low
monocyte mCD14 expression. At the time of maxi-
mal mCD14 suppression, the levels of sCD14 were
clearly increased by factor of 1.7 (before CPB 3.2 6
1.0 vs 5.6 6 1.0 mg/ml 20 hours after operation, p ,
0.001, Fig. 3, A). Levels of sCD14 in plasma (total
sCD14) derive from a small membrane form of
CD14 (sCD14a) and from intracellular pools
(sCD14b).17 In our study no significant change was
found in the relative contribution of the a-form and
the b-form to total sCD14 levels (a-sCD14: at 0
Fig. 2. Expression of mCD14 on CD1411 monocytes. Expression of mCD14 on CD1411 monocytes was
analyzed with the monoclonal antibody My4-PE and the respective isotypic control. Preoperative values
(t 5 0) were taken as 100%. Subsequent data are given as relative difference to preoperative values
(sMFI[t] divided by sMFI[t 5 0]), thus reflecting the decrease compared with t 5 0. Statistical differences
are described in the text. sMFI, Specific mean fluorescence; CPB, cardiopulmonary bypass.
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hours 55% 6 2% of total vs 51% 6 3% of total 20
hours after). In Fig. 3, B, representative data ob-
tained from one patient are shown. In this patient
the relative contribution of sCD14 to total sCD14
was essentially constant (59% at 0 hours and 64% 20
hours after operation). Thus secretion of intracellu-
lar material and shedding of mCD14 from the
monocyte surface appear to contribute equally to
the increase of total sCD14.
Discussion
Despite considerable progress in the use of CPB,
the so-called postperfusion syndrome still plays a
role in the morbidity and mortality of patients
undergoing cardiac operations, particularly after
prolonged extracorporeal circulation. The underly-
ing mechanism(s) of this inflammatory response is
still not fully understood. Functional and phenotypic
signs of leukocyte activation during extracorporeal
circulation for cardiac operation have been reported
previously.1, 2 In this regard leukocyte-mediated vas-
cular endothelial damage is believed to play a major
role, with most of the studies focused on the gener-
ation of activated complement components (C5a) or
the release of leukocyte-derived cytokines (IL-1,
IL-6, IL-8, tumor necrosis factor-a).
Besides generation of proinflammatory soluble
cell products, monocytes express a specific 55-kD
glycoprotein on their surface, the CD14 antigen that
exists in both the membrane-associated and soluble
form. The CD14 antigen system is of principal
importance in stimulation of monocytes by endo-
toxin and endotoxin-like substances. In this study
the effect of cardiac bypass operation on the mono-
cyte CD14 system was investigated.
Herein a profound alteration of the monocyte
CD14 system was found in patients undergoing
elective coronary revascularization. After cardiac
operation with the use of CPB, a significant mono-
cytosis was observed, reaching a maximum at 20
hours after operation. In parallel to this increase of
monocyte cell number, a decrease of mCD14 anti-
gen expression and a significant increase in levels of
sCD14 antigen occurred in all patients studied.
Bacterial LPS is a potent activator of leukocytes,
with CD14 on the cell membrane as the main LPS
receptor. LPS may associate with soluble serum
proteins (LPS binding protein) before the resulting
complex is bound by mCD14, leading to character-
istic cell responses such as synthesis and release of
inflammatory mediators. In addition, CD14 can be
released by leukocytes, and the soluble form of
CD14 has been shown to enable responses to LPS by
cells that do not express CD14 as an LPS receptor,18
as well as by mCD14-bearing cells.19, 20 These activ-
ities indicate that the membrane form behaves as an
LPS receptor, and its soluble pendant may serve as
a coligand for LPS-mediated cell activation.
The decrease of membrane CD14 on blood
monocytes and the concomitant increase of sCD14
in plasma reported herein suggest that the sCD14 is
derived from monocytes by shedding of the cell
surface molecule. In addition, it is possible that
tissue macrophages contribute to the increased
Fig. 3. Levels of sCD14 before and 20 hours after aorta-coronary bypass operation. A, Total levels of
sCD14 were determined by Western blotting at 0 hours and 20 hours after operation with the My4
monoclonal antibody and were visualized by enhanced chemiluminescence. Values are given as mean 6
standard deviation. Statistical differences are described in the text. B, Representative Western blot of the
a-form and b-form of sCD14 in patient No. 1 at 0 hours and 20 hours after operation. Here, the a-form
(lower band) accounts for 59% of total sCD14 before and 64% 20 hours after operation.
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sCD14 by the same mechanism. At this point it is,
however, not known whether mCD14 of tissue mac-
rophages also becomes down-regulated after CPB.
Although anti-CD14 monoclonal antibodies pref-
erentially stain monocytes and macrophages, reac-
tivity with other cells, such as granulocytes, B cells,
and mammary cells, is also observed.21 Besides
activation of monocytes, CPB may lead to significant
alterations in granulocytes. Indeed, increased
plasma concentrations of granulocyte proteinases
and oxygen radicals have been reported.22 There-
fore granulocytes and monocytes should be consid-
ered as the source of sCD14 found after CPB.
CD14 in plasma is found as a mixture of two
soluble proteins, the smaller molecular weight
sCD14a, deriving mainly from membrane-bound
protein material by shedding, and the larger molec-
ular weight sCD14b, released from intracellular
pools.17 In this study we found no significant differ-
ence in the ratio of the a and the b forms of sCD14
between samples taken before and after operation.
These results indicate that secretion of intracellular
material and shedding of mCD14 contribute equally
to the increase of total sCD14 found in plasma after
coronary bypass operation.
In vitro LPS stimulation of monocytes induces an
increase of mCD14 expression within 30 minutes
followed by a slow decrease after 1 to 3 hours.23
Furthermore, this decrease of mCD14 coincides
with an enhanced sCD14 release by the stimulated
cells.24 In our study a transient increase of mCD14
expression immediately after the start of CPB was
followed by a continuous decrease of mCD14. Sim-
ilar to the in vitro results reported, these changes in
membrane-bound antigen activity paralleled the in-
creasing levels of sCD14, reaching a maximum at 20
hours after the end of operation. Our results indi-
cate that CPB poses a strong stimulus to previously
unaffected circulating monocytes.
Several mechanisms of cell activation during
CPB have been proposed. Direct interaction of
immunocompetent blood cells with the foreign
surfaces of the extracorporeal circuit has been
favored as the primary mechanism.1 However,
with its biologic function as the main LPS recep-
tor on leukocytes, the CD14 system could mediate
activation of cells by endotoxin itself. Indeed, in
patients undergoing CPB, increased intestinal
permeability and significantly elevated levels of
plasma endotoxin activity measured by the Limu-
lus amebocyte lysate assay have been reported.25
Furthermore, as found with other extracorporeal
circuits, such as hemodialysis and hemofiltration,
monocyte activation could be due to contamina-
tion of blood, tubing lines, the membrane oxygen-
ator, or the priming solution with endotoxin or
endotoxin-like material.26 Interestingly, a reduced
expression of mCD14, together with elevated se-
rum levels of sCD14, was also described in pa-
tients undergoing intermittent hemodialysis.27 In
addition, the operative trauma itself, ischemia-
reperfusion injury caused by crossclamping of the
aorta, and reinfusion of shed blood could contrib-
ute to the cell-activating process.
On the basis of our results, we speculate that
endothelial cell responses after CPB occur through
different pathways. One pathway, probably the prin-
cipal pathway, is activation of monocytes through
mCD14 triggering a complex inflammatory re-
sponse, including the production and release of
cytokines, reactive oxygen species, and prostanoids,
all of which are known to be able to induce vascular
endothelial cell damage directly. In addition, activa-
tion of the CD14 system could induce increased
shedding and release of sCD14. The soluble form of
CD14 then could interact with endothelial cells,
promoting cell activation indirectly in concert with
inflammatory cytokines.21 In our study we did not
include the measurement of cytokine production.
However, in patients with sepsis, LPS-mediated
signaling and cytokine transcription were reported
unchanged despite a significant decrease of CD14
expression on blood monocytes.28 Finally, endothe-
lial cell activation and damage may also be induced
by direct leukocyte endothelial interaction mediated
by adhesion molecules.29
In conclusion, our results demonstrate that
cardiac operation with the use of CPB results in
significantly decreased mCD14 and elevated
sCD14 levels, indicating a profound derangement
of the CD14 receptor system. The clinical impor-
tance of these findings is not yet clear. In septice-
mic patients both decreased as well as unchanged
CD14 expression by blood monocytes has also
been reported.16, 30 These different results might
be explained by different subsets of patients or
different times of cell surface antigen analysis.
Furthermore, elevated plasma levels of sCD14
were associated with a higher mortality in patients
with sepsis or multiple organ failure. However,
whether these changes contribute to a quantita-
tive and functional impairment of the immune
response in patients undergoing cardiac operation
cannot be concluded from this study.
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